Literature DB >> 9361153

The mechanism of action of methotrexate.

B N Cronstein1.   

Abstract

Because of methotrexate's well-documented efficacy in the treatment of rheumatoid arthritis, it is important that we understand the mechanism of action of this drug. There are two biochemical mechanisms by which methotrexate may modulate inflammation: (1) promotion of adenosine release and (2) inhibition of transmethylation reactions. Evidence is reviewed that favors the notion that the endogenous anti-inflammatory autocoid adenosine mediates the anti-inflammatory effects of methotrexate. This insight should aid in the design of new agents for the treatment of rheumatoid arthritis and other inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361153     DOI: 10.1016/s0889-857x(05)70358-6

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  35 in total

Review 1.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis.

Authors:  M Cutolo; A Sulli; C Pizzorni; B Seriolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

Review 2.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

3.  Adverse effects of methotrexate in three psoriatic arthritis patients.

Authors:  Hideki Maejima; Akira Watarai; Toshiaki Nakano; Chieko Katayama; Hiromi Nishiyama; Kensei Katsuoka
Journal:  Rheumatol Int       Date:  2012-12-29       Impact factor: 2.631

4.  Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.

Authors:  Anthoula Chatzikyriakidou; Ioannis Georgiou; Paraskevi V Voulgari; Christos G Papadopoulos; Theodoros Tzavaras; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2007-04-03       Impact factor: 2.631

5.  Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis.

Authors:  Amita Aggarwal; Ramnath Misra
Journal:  Rheumatol Int       Date:  2003-03-07       Impact factor: 2.631

Review 6.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Four-year experience with methotrexate exposures.

Authors:  Frank LoVecchio; Kenneth Katz; David Watts; Ian Wood
Journal:  J Med Toxicol       Date:  2008-09

8.  Adipose-derived stem cells retain their regenerative potential after methotrexate treatment.

Authors:  Olivia S Beane; Vera C Fonseca; Eric M Darling
Journal:  Exp Cell Res       Date:  2014-06-30       Impact factor: 3.905

Review 9.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury.

Authors:  Tobias Eckle; Kelly Hughes; Heidi Ehrentraut; Kelley S Brodsky; Peter Rosenberger; Doo-Sup Choi; Katya Ravid; Tingting Weng; Yang Xia; Michael R Blackburn; Holger K Eltzschig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.